Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

J. Zhou; Y. L.A. Chau; J. W. Yoo; S. Lee; K. Ng; E. C. Dee; T. Liu; A. K.C. Wai; Q. Zhang; G. Tse

doi:10.1016/j.clon.2022.03.006

Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

J. Zhou
, Y. L.A. Chau
, J. W. Yoo
, S. Lee
, K. Ng
, E. C. Dee
, T. Liu
, A. K.C. Wai
, Q. Zhang
, G. Tse

Research output: Contribution to journal › Letter › peer-review

11 Citations (Scopus)

Original language	English
Pages (from-to)	e316-e317
Journal	Clinical Oncology
Volume	34
Issue number	7
DOIs	https://doi.org/10.1016/j.clon.2022.03.006
Publication status	Published - Jul 2022
Externally published	Yes

Access to Document

10.1016/j.clon.2022.03.006

Cite this

Zhou, J., Chau, Y. L. A., Yoo, J. W., Lee, S., Ng, K., Dee, E. C., Liu, T., Wai, A. K. C., Zhang, Q., & Tse, G. (2022). Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses. Clinical Oncology, 34(7), e316-e317. https://doi.org/10.1016/j.clon.2022.03.006

@article{62a562f5ded5444aacd45fac27cc479b,

title = "Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses",

author = "J. Zhou and Chau, \{Y. L.A.\} and Yoo, \{J. W.\} and S. Lee and K. Ng and Dee, \{E. C.\} and T. Liu and Wai, \{A. K.C.\} and Q. Zhang and G. Tse",

year = "2022",

month = jul,

doi = "10.1016/j.clon.2022.03.006",

language = "English",

volume = "34",

pages = "e316--e317",

number = "7",

}

Zhou, J, Chau, YLA, Yoo, JW, Lee, S, Ng, K, Dee, EC, Liu, T, Wai, AKC, Zhang, Q & Tse, G 2022, 'Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses', Clinical Oncology, vol. 34, no. 7, pp. e316-e317. https://doi.org/10.1016/j.clon.2022.03.006

TY - JOUR

T1 - Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors

T2 - A Propensity Score Matched Study with Competing Risk Analyses

AU - Zhou, J.

AU - Chau, Y. L.A.

AU - Yoo, J. W.

AU - Lee, S.

AU - Ng, K.

AU - Dee, E. C.

AU - Liu, T.

AU - Wai, A. K.C.

AU - Zhang, Q.

AU - Tse, G.

PY - 2022/7

Y1 - 2022/7

UR - https://www.scopus.com/pages/publications/85131828161

U2 - 10.1016/j.clon.2022.03.006

DO - 10.1016/j.clon.2022.03.006

M3 - Letter

C2 - 35321832

AN - SCOPUS:85131828161

SN - 0936-6555

VL - 34

SP - e316-e317

JO - Clinical Oncology

JF - Clinical Oncology

IS - 7

ER -

Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

Access to Document

Other files and links

Cite this